Tiziana Life Sciences Raises $8.8m for Intranasal Foralumab Development
January 16, 2026
Tiziana Life Sciences closes oversubscribed $8.8m registered direct offering of 7.04m shares at $1.25/share to fund intranasal foralumab trials.
January 16, 2026
Tiziana Life Sciences closes oversubscribed $8.8m registered direct offering of 7.04m shares at $1.25/share to fund intranasal foralumab trials.